Barron E, Marshall R J, Martorana M, Winslow E
Br J Pharmacol. 1986 Nov;89(3):603-12. doi: 10.1111/j.1476-5381.1986.tb11162.x.
The potential antiarrhythmic and electrophysiological actions of drugs known to inhibit calmodulin, i.e. trifluoperazine (TFP) and N-(6-aminohexyl)-5-chloro-1-naphthalene sulphonamide (W7) have been compared with bepridil, whose antiarrhythmic actions have previously been ascribed to blockade of the fast inward sodium current in cardiac tissue. Like bepridil, both TFP and W7 reduced the severity of arrhythmias evoked by 30 min of coronary artery occlusion in the anaesthetized rat. TFP (2.5-10 mg kg-1, i.v.), W7 (2.5-10 mg kg-1, i.v.) and bepridil (1-5 mg kg-1, i.v.) also antagonized the development of ventricular fibrillation induced by 5 min of occlusion followed by reperfusion. All three drugs also reduced mortality. TFP and bepridil also reduced the incidence of reperfusion-induced ventricular tachycardia whilst all 3 drugs reduced its duration. Although TFP was shown to possess alpha-adrenoceptor blocking properties, the classical alpha-blocker, phentolamine, failed to reduce significantly the incidence or severity of reperfusion arrhythmias. In contrast to bepridil (2-20 microM), which markedly reduced the maximum rate of depolarization (Vmax) of guinea-pig isolated papillary muscle, W7(5-50 microM) showed only weak effects on Vmax and was at least 10 times less potent than bepridil whilst TFP only reduced Vmax in high concentrations (40-100 microM) which lowered resting membrane potential. Unlike bepridil, neither TFP (4-40 microM) nor W7 prolonged the absolute refractory period. The results suggest that drugs which inhibit calmodulin confer protection against both ischaemia-and reperfusion-induced arrhythmias in the rat. Although the electrophysiological actions of bepridil would adequately account for its antiarrhythmic activity, the same cannot be said of W7 and especially TFP. In conclusion, calmodulin antagonism may constitute a mechanism of antiarrhythmic activity.
已知抑制钙调蛋白的药物,即三氟拉嗪(TFP)和N-(6-氨基己基)-5-氯-1-萘磺酰胺(W7)的潜在抗心律失常和电生理作用,已与苄普地尔进行了比较,苄普地尔的抗心律失常作用先前被归因于对心脏组织快速内向钠电流的阻断。与苄普地尔一样,TFP和W7均降低了麻醉大鼠冠状动脉闭塞30分钟诱发的心律失常的严重程度。TFP(2.5 - 10 mg·kg⁻¹,静脉注射)、W7(2.5 - 10 mg·kg⁻¹,静脉注射)和苄普地尔(1 - 5 mg·kg⁻¹,静脉注射)也拮抗了5分钟闭塞后再灌注诱发的心室颤动的发展。这三种药物均降低了死亡率。TFP和苄普地尔还降低了再灌注诱发的室性心动过速的发生率,而三种药物均缩短了其持续时间。尽管已证明TFP具有α-肾上腺素能受体阻断特性,但经典的α-阻滞剂酚妥拉明未能显著降低再灌注心律失常的发生率或严重程度。与苄普地尔(2 - 20 μM)显著降低豚鼠离体乳头肌的最大去极化速率(Vmax)相反,W7(5 - 50 μM)对Vmax仅表现出微弱作用,其效力至少比苄普地尔低10倍,而TFP仅在高浓度(40 - 100 μM)时降低Vmax,此时静息膜电位降低。与苄普地尔不同,TFP(4 - 40 μM)和W7均未延长绝对不应期。结果表明,抑制钙调蛋白的药物可保护大鼠免受缺血和再灌注诱发的心律失常。尽管苄普地尔的电生理作用足以解释其抗心律失常活性,但W7尤其是TFP并非如此。总之,钙调蛋白拮抗作用可能构成抗心律失常活性的一种机制。